Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
Date:9/24/2009

ma, please go to www.cancer.org.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase 1/2 and Phase 2 human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

The Cancer Therapy Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the nation's leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only three in Texas. A world leader in developing new drugs to treat cancer, The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participates in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food Drug Administration. For more information, visit our Web site at www.ctrc.net.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase 2 combination REOLYSIN/paclitaxel and
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
4. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 Research and ... the  "North America Portable X Ray Devices Market ...  report to their offering.       (Logo: ... market for Portable X-Ray Devices is ... 2014 to 2020 X-Ray is a ...
(Date:5/27/2015)... 27, 2015 The global vitreoretinal ... market with analysis and forecast of revenue. This market ... is estimated to grow at a CAGR of 8.9 ... the TOC of the global vitreoretinal surgery devices market ... provided. This report also provides a glimpse of the ...
(Date:5/27/2015)... 2015  Marcio Donatelli, a senior marketing associate with the animal health ... volunteer work in a healthcare setting in Bangkok, Thailand ... for people in need with respect and dignity is the guiding star ... -based Elanco employee in a LillyPad blog . Donatelli ... , Colombia , France , ...
Breaking Medicine Technology:North America Portable X Ray Devices Market Report 2015 - Growth, Trends And Forecasts 2014-2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3
... Md., May 16, 2011 Science, public health, and ... Drug Administration. Information in this document is designed for credentialed ... of May 16, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... any regulatory or enforcement actions due to legal limitations. ...
... RATON, Fla., May 16, 2011 Breckenridge Pharmaceutical, ... have reached an agreement with Takeda Pharmaceutical Company ... litigation related to Pioglitazone Hydrochloride 15 mg, 30 ... version of Actos®. Under the terms of the ...
Cached Medicine Technology:FDA News & Notes - Week of May 16, 2011 2FDA News & Notes - Week of May 16, 2011 3Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation 2
(Date:5/27/2015)... CA (PRWEB) May 27, 2015 Khanna Vision ... the art web portal focussed on keratoconus eye disease ... relentless progressive disease has its onset in the teenage years. ... The cornea or the front clear part of the eye ... pressure in the eye. It results in poor vision which ...
(Date:5/27/2015)... Wis. (PRWEB) May 27, 2015 “We ... Julie Schuller, MD, executive vice president and vice president ... this grant makes possible allows us to provide comprehensive ... of our community.” , SSCHC provides clinical care and ... over 35,000 people in 2014, many of whom took ...
(Date:5/27/2015)... May 27, 2015 Hundreds of ... behalf of individuals who allegedly suffered gynecomastia (male ... use of the antipsychotic drug continue to move ... in Pennsylvania’s Philadelphia Court of Common Pleas. According ... its bellwether trial program, as the third trial ...
(Date:5/27/2015)... 27, 2015 With the launch of ... robust Network Management Module (NMM) tool, monitoring provider-network adequacy ... issue of Atlantic Information Services, Inc.’s (AIS) Medicare Advantage ... tool, as well as analysis from industry experts on ... changes coming to the NMM were announced at CMS’s ...
(Date:5/27/2015)... 27, 2015 In today's healthcare landscape, ... it can be challenging for doctors and hospitals to ... treatments. , Austin-based HealthTronics, Inc. is ... mobile medical therapies for clinically sophisticated applications. The company ... acquisition of Laser Ventures, Inc ., a mobile ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:Sixteenth Street Community Health Centers To Expand Primary Care and Behavioral Health Services Through $1 Million Grant From Aurora's Better Together Fund 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3
... , PURCHASE, N.Y., Aug. 12 ... on a preliminary and unaudited basis it expects revenues for the ... that it expects to incur a net loss for the quarter ... for intangible assets. Operating profit for the fiscal year is ...
... Finding runs counter to standard advice doctors have given for ... can help prevent flare-ups of lymphedema, a painful swelling of ... research shows. , The finding runs counter to what women ... stressing the arm during strength training or other exercise because ...
... brain abnormalities may cause learning problems, study finds, , ... with epilepsy should have their language, memory, learning and ... for problems, say U.S. researchers. , The recommendation stems ... IQ of at least 70 who had experienced their ...
... , , , ... ,Honorary Ambassador, By Project Lifesaver International , , ... Lifesaver International, a non-profit organization that helps rescue citizens that ... honored Erik Estrada at a ceremony Sunday in Lynchburg, Virginia. ...
... , , CLEVELAND, Aug. 12 ... Shannon Fogarty Jerse to its legal department. Jerse will serve as ... role as Deputy General Counsel for the health system. , ... the breadth of legal expertise that Shannon brings to this new ...
... , NEW YORK, Aug. 12 Gloria ... Ogilvy Healthworld North America, have been appointed Joint Worldwide CEOs of ... , , In making the announcement, Mr. Young ... are also very complementary individuals. Their joint mandate is to ...
Cached Medicine News:Health News:Nutrition 21 Announces Preliminary Fourth Quarter Financial Update Also Announces Negotiations on Notes due August 25, 2009 2Health News:Weight Lifting Can Ease Arm Swelling in Breast Cancer Survivors 2Health News:Weight Lifting Can Ease Arm Swelling in Breast Cancer Survivors 3Health News:Experts Urge Cognitive Testing of Kids With Epilepsy 2Health News:Erik Estrada Accepts Honorary Appointment from Project Lifesaver International 2Health News:Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 2Health News:Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 3Health News:Joint Worldwide CEO's of Ogilvy Healthworld Named 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: